- Home
- WBX vs HLVX Comparison
WBX vs HLVX Comparison
Compare WBX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- HLVX
- Stock Information
- Founded
- WBX 2015
- HLVX 2020
- Country
- WBX Spain
- HLVX United States
- Employees
- WBX N/A
- HLVX N/A
- Industry
- WBX Industrial Specialties
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- WBX Consumer Discretionary
- HLVX Health Care
- Exchange
- WBX Nasdaq
- HLVX Nasdaq
- Market Cap
- WBX 104.7M
- HLVX 105.2M
- IPO Year
- WBX N/A
- HLVX 2022
- Fundamental
- Price
- WBX $4.35
- HLVX $2.07
- Analyst Decision
- WBX Buy
- HLVX Hold
- Analyst Count
- WBX 4
- HLVX 1
- Target Price
- WBX $10.50
- HLVX $2.00
- AVG Volume (30 Days)
- WBX 20.3K
- HLVX 796.7K
- Earning Date
- WBX 07-31-2025
- HLVX 08-06-2025
- Dividend Yield
- WBX N/A
- HLVX N/A
- EPS Growth
- WBX N/A
- HLVX N/A
- EPS
- WBX N/A
- HLVX N/A
- Revenue
- WBX $173,788,608.00
- HLVX N/A
- Revenue This Year
- WBX N/A
- HLVX N/A
- Revenue Next Year
- WBX $36.47
- HLVX N/A
- P/E Ratio
- WBX N/A
- HLVX N/A
- Revenue Growth
- WBX N/A
- HLVX N/A
- 52 Week Low
- WBX $4.21
- HLVX $1.34
- 52 Week High
- WBX $31.80
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- WBX 42.94
- HLVX 50.94
- Support Level
- WBX $4.21
- HLVX $2.07
- Resistance Level
- WBX $5.13
- HLVX $2.10
- Average True Range (ATR)
- WBX 0.36
- HLVX 0.06
- MACD
- WBX -0.38
- HLVX -0.01
- Stochastic Oscillator
- WBX 0.00
- HLVX 41.18
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.